U.S. breast surgeons will now have access to an intra-operative tissue assessment tool for early-stage breast cancer surgery. Dune Medical Devices (Boston) said it has received premarket approval from the FDA for its MarginProbe system. According to the company, the technology significantly improves surgeons' ability to intra-operatively identify cancer margins and reduce pathologically positive margins following a patient's initial lumpectomy surgery.